News
-
July Pharmacist
Tuesday | Jul 7 2015This month’s Australian Pharmacist includes an update on bullying in the workplace, reflecting new measures due.
-
FDA ticks Orkambi
Tuesday | Jul 7 2015Orkambi (lumacaftor 200 mg with ivacaftor 125 mg), for cystic fibrosis has now been approved for.
-
‘Doc around the clock’
Tuesday | Jul 7 2015In a joint venture between Telstra Health and Swiss telemedicine provider Medgate, a new ‘ReadyCare’ 24-hour.
-
MA pushes transparency
Tuesday | Jul 7 2015Medicines Australia (MA) has launched an awareness campaign to ensure healthcare professionals are aware of and.
-
Safety Related Changes 06 Jul 15
Monday | Jul 6 2015Eliquis (apixaban) is now indicated for the treatment of deep vein thrombosis (DVT) and pulmonary embolism.
-
Lucrin Depot Paediatric Prefilled dual chamber syringe (pds) Injection 3 Month (leuprorelin acetate)
Monday | Jul 6 2015Lucrin Depot Paediatric Prefilled dual chamber syringe (pds) Injection 3 Month (leuprorelin acetate) is a synthetic.
-
Javlor (vinflunine ditartrate)
Monday | Jul 6 2015Javlor (vinflunine ditartrate) binds to tubulin at or near to the vinca binding sites inhibiting its.
-
Harvoni (ledipasvir/sofosbuvir)
Monday | Jul 6 2015Harvoni (ledipasvir/sofosbuvir) contains a HCV NS5A inhibitor (ledipasvir) and a nucleotide inhibitor of HCV NS5B RNA‑dependent.
-
Adenuric (febuxostat)
Monday | Jul 6 2015Adenuric (febuxostat) is a potent, nonpurine, selective inhibitor of xanthine oxidase (XO) that prevents the normal.
-
Weekly Comment 06 Jul 15
Monday | Jul 6 2015Advancing Practice: formal recognition of your professional impact.